Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants
- PMID: 23726462
- DOI: 10.1016/j.parkreldis.2013.05.003
Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants
Abstract
Mutations in the LRRK2 and GBA genes are increasingly recognized as frequent determinants of familial and sporadic Parkinson's disease (PD). However, for several populations, accurate data on the prevalence and types of mutations are not available, because previous studies have not investigated the complete coding regions of these genes in large samples. We studied 312 PD patients ascertained at a single centre in Lisbon, Portugal. In 61 patients, with familial PD, we sequenced the entire open reading frames and exon-intron boundaries of LRRK2 and GBA. In LRRK2, we identified ten heterozygous p.Gly2019Ser (16.4%), and two heterozygous p.Arg1441His carriers (3.3%); furthermore, six patients each carried a novel LRRK2 heterozygous variant (five coding and one 3'-UTR variants) of undetermined pathogenic role. Segregation of the p.Arg1441His mutation with PD was observed in the families of both carriers. None of these variants were identified in 138 healthy controls. Screening of GBA revealed no mutations. In the remaining 251 PD patients (25 familial and 226 sporadic) we found ten additional carriers of the heterozygous p.Gly2019Ser and no carriers of the other mutations. Thus, the p.Gly2019Ser mutation was detected in a total number of 20 carriers out of 312 patients (6.4%), including twelve familial (14%) and eight sporadic patients (3.5%). This comprehensive study confirms that p.Gly2019Ser is the most important genetic cause of PD known so far in Portugal and supports the contention that p.Arg1441His is also a PD-causing mutation. These findings have relevance for the genetic testing and counseling of PD patients in this population.
Keywords: GBA; Genetics; LRRK2; Parkinson's disease; Portugal; R1441H.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.Mov Disord. 2007 Jun 15;22(8):1194-201. doi: 10.1002/mds.21525. Mov Disord. 2007. PMID: 17469194
-
Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.Parkinsonism Relat Disord. 2012 Jun;18(5):567-71. doi: 10.1016/j.parkreldis.2012.02.018. Epub 2012 Mar 24. Parkinsonism Relat Disord. 2012. PMID: 22445250
-
Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.J Alzheimers Dis. 2014;38(2):351-7. doi: 10.3233/JAD-130689. J Alzheimers Dis. 2014. PMID: 23963289
-
LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.Neurochem Res. 2007 Oct;32(10):1700-8. doi: 10.1007/s11064-007-9324-y. Epub 2007 Apr 18. Neurochem Res. 2007. PMID: 17440812 Review.
-
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.Adv Neurobiol. 2017;14:3-30. doi: 10.1007/978-3-319-49969-7_1. Adv Neurobiol. 2017. PMID: 28353276 Review.
Cited by
-
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845. Biomolecules. 2023. PMID: 37238714 Free PMC article. Review.
-
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.Neurotherapeutics. 2014 Oct;11(4):738-50. doi: 10.1007/s13311-014-0284-z. Neurotherapeutics. 2014. PMID: 24957201 Free PMC article. Review.
-
Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.Front Neurosci. 2022 Sep 20;16:971270. doi: 10.3389/fnins.2022.971270. eCollection 2022. Front Neurosci. 2022. PMID: 36203807 Free PMC article. Review.
-
A Next-Generation Sequencing Study in a Cohort of Sicilian Patients with Parkinson's Disease.Biomedicines. 2023 Nov 22;11(12):3118. doi: 10.3390/biomedicines11123118. Biomedicines. 2023. PMID: 38137339 Free PMC article.
-
Genetic Testing in Parkinson's Disease.Mov Disord. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27. Mov Disord. 2023. PMID: 37365908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical